Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Status:
Recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy
followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic
syndromes (MDS) or acute myeloid leukemia (AML). [(FDA OOPD)]
Phase:
Phase 1
Details
Lead Sponsor:
Montefiore Medical Center
Collaborators:
Flamingo Therapeutics NV M.D. Anderson Cancer Center